154 related articles for article (PubMed ID: 2239483)
1. Bromocriptine and levodopa in early combination in Parkinson's disease: first results of the Collaborative European Multicentric Trial.
Olsson JE
Adv Neurol; 1990; 53():421-3. PubMed ID: 2239483
[No Abstract] [Full Text] [Related]
2. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
Rascol O; Fabre N; Blin O; Poulik J; Sabatini U; Senard JM; Ané M; Montastruc JL; Rascol A
Mov Disord; 1994 Jul; 9(4):437-40. PubMed ID: 7969211
[TBL] [Abstract][Full Text] [Related]
3. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
Grimes JD; Delgado MR
Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
[TBL] [Abstract][Full Text] [Related]
4. [Secondary effects of prolonged levodopa therapy in Parkinson's disease].
Peiró Grasa A; Grau-Veciana JM
Med Clin (Barc); 1985 Jun; 85(3):88-91. PubMed ID: 4021630
[No Abstract] [Full Text] [Related]
5. A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan.
Nakanishi T; Mizuno Y; Goto I; Iwata M; Kanazawa I; Kowa H; Mannen T; Nishitani H; Ogawa N; Takahashi A
Eur Neurol; 1988; 28 Suppl 1():3-8. PubMed ID: 3378560
[TBL] [Abstract][Full Text] [Related]
6. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.
Pezzoli G; Martignoni E; Pacchetti C; Angeleri VA; Lamberti P; Muratorio A; Bonuccelli U; De Mari M; Foschi N; Cossutta E
Mov Disord; 1994 Jul; 9(4):431-6. PubMed ID: 7969210
[TBL] [Abstract][Full Text] [Related]
7. [L-dopa and bromocriptine in Parkinson disease. Early combination therapy has better effect].
Olsson JE; Duchek M; Ekberg R; Fehling C; Johansson F; Johnels B; Lindvall B; Nordin G; Sidén A; Steg G
Lakartidningen; 1993 Apr; 90(16):1545-8. PubMed ID: 8483351
[No Abstract] [Full Text] [Related]
8. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
Ulm G
Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619
[No Abstract] [Full Text] [Related]
9. Clinical experience with duodenal infusions of levodopa for the treatment of motor fluctuations in Parkinson's disease.
Sage JI; Sonsalla PK; McHale DM; Heikkila RE; Duvoisin RC
Adv Neurol; 1990; 53():383-6. PubMed ID: 2122646
[No Abstract] [Full Text] [Related]
10. [Comparison of administration of low doses of bromocriptine and levodopa in the early treatment of Parkinson disease].
Sternić N; Kostić V
Srp Arh Celok Lek; 1992; 120(1-2):1-5. PubMed ID: 1641693
[TBL] [Abstract][Full Text] [Related]
11. A nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. The fourth interim report.
Nakanishi T; Mizuno Y; Goto I; Iwata M; Kanazawa I; Kowa H; Mannen T; Nishitani H; Ogawa N; Takahashi A
Eur Neurol; 1991; 31 Suppl 1():3-16. PubMed ID: 1906808
[TBL] [Abstract][Full Text] [Related]
12. Early combination therapy with bromocriptine and levodopa in Parkinson's disease.
Factor SA; Weiner WJ
Mov Disord; 1993 Jul; 8(3):257-62. PubMed ID: 8341289
[TBL] [Abstract][Full Text] [Related]
13. Bromocriptine and lisuride in Parkinson's disease.
Caraceni T; Giovannini P; Parati E; Scigliano G; Grassi MP; Carella F
Adv Neurol; 1984; 40():531-5. PubMed ID: 6695632
[No Abstract] [Full Text] [Related]
14. [The treatment of Parkinson disease using the combination bromocriptine and levodopa].
Dufresne JJ
Rev Med Suisse Romande; 1990 Jun; 110(6):559-64. PubMed ID: 2367793
[No Abstract] [Full Text] [Related]
15. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R
Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
[TBL] [Abstract][Full Text] [Related]
16. Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease.
Contin M; Riva R; Martinelli P; Baruzzi A
Mov Disord; 1992; 7(3):244-8. PubMed ID: 1620142
[TBL] [Abstract][Full Text] [Related]
17. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
Zimmerman TR; Sage JI; Lang AE; Mark MH
Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
[TBL] [Abstract][Full Text] [Related]
18. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
19. Early combination of dopamine agonist and levodopa in the treatment of Parkinson's disease.
Rinne UK
Mt Sinai J Med; 1988 Mar; 55(2):138-41. PubMed ID: 3260342
[No Abstract] [Full Text] [Related]
20. Motor response complications with chronic levodopa therapy.
Chase TN; Fabbrini G; Juncos JL; Mouradian MM
Adv Neurol; 1990; 53():377-81. PubMed ID: 2239478
[No Abstract] [Full Text] [Related]
[Next] [New Search]
